<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241640</url>
  </required_header>
  <id_info>
    <org_study_id>SI 001/2020</org_study_id>
    <nct_id>NCT04241640</nct_id>
  </id_info>
  <brief_title>Nefopam for Post Video-Assisted Thoracoscopic Lobectomy</brief_title>
  <official_title>Nefopam for Post Video-Assisted Thoracoscopic Lobectomy Pain Management and the Improvement of Enhanced Recovery After Surgery (ERAS): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Video-assisted thoracoscopic (VATs) lobectomy is mild to moderately pain procedure. For
      conventional thoracotomy, there are many invasive pain control such as epidural analgesia,
      paravertebral block. However, for VATs, the invasive pain control somehow are too invasive.
      Nefopam is non-opioid painkilling medication, Serotonin, norepinephrine, dopamine reuptake
      inhibitor. Many study were demonstrated positive outcome of nefopam usage in many operation
      such as abdominal surgery, laparocopic surgery, orthopedic surgery. Nevertheless, nefopam for
      VATs is not well studied yet.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption in first 24 hours post-operative</measure>
    <time_frame>24 hours</time_frame>
    <description>morphine consumption record from patient-controlled analgesia machine in 24 hours post-operative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>numeric pain score</measure>
    <time_frame>24 hours</time_frame>
    <description>numeric pain score in 1, 2, 12, 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect of nefopam</measure>
    <time_frame>24 hours</time_frame>
    <description>side effect of nefopam: tachycardia, sweating, nausea, vomiting, sedation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Nefopam group[</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam 20 MG/ML</intervention_name>
    <description>Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative</description>
    <arm_group_label>Nefopam group[</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schedule to video-assisted thoracoscopic surgery : VATs lobectomy

          -  Can operate a patient-controlled analgesia (PCA) device

          -  No contraindication for nefopam

        Exclusion Criteria:

          -  Epilepsy, on monoamine oxidase (MAO) inhibitors, glaucoma

          -  Creatinine clearance &lt; 60 ml/min

          -  Liver disease: child-pugh score B or C

          -  Allergy to nefopam

          -  Chronic opioid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chaowanan Khamtuikrua, MD</last_name>
    <phone>+6624197990</phone>
    <phone_ext>113</phone_ext>
    <email>ckhamtuicrua@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sirilak Suksompong, MD</last_name>
    <phone>+6624197990</phone>
    <phone_ext>113</phone_ext>
    <email>ssuksompong5@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>faculty of medicine Siriraj hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10600</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Chaowanan Khamtuikrua, MD</last_name>
      <phone>+6624197990</phone>
      <phone_ext>113</phone_ext>
      <email>Ckhamtuicrua@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sirilak Suksompong, MD</last_name>
      <phone>+6624197990</phone>
      <phone_ext>113</phone_ext>
      <email>ssuksompong5@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Chaowanan Khamtuikrua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

